Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 49 citing articles:

An update on COVID-19: SARS-CoV-2 variants, antiviral drugs, and vaccines
V. Edwin Hillary, Stanislaus Antony Ceasar
Heliyon (2023) Vol. 9, Iss. 3, pp. e13952-e13952
Open Access | Times Cited: 76
Improved DNA Vaccine Delivery with Needle-Free Injection Systems
Carmen Ledesma‐Feliciano, Rosamund Chapman, Jay W. Hooper, et al.
Vaccines (2023) Vol. 11, Iss. 2, pp. 280-280
Open Access | Times Cited: 62
A Brief Review on Dna Vaccines in the Era of COVID-19
Maryam Shafaati, Massoud Saidijam, Meysam Soleimani, et al.
Future Virology (2021) Vol. 17, Iss. 1, pp. 49-66
Open Access | Times Cited: 91
Safety and immunogenicity of a synthetic multiantigen modified vaccinia virus Ankara-based COVID-19 vaccine (COH04S1): an open-label and randomised, phase 1 trial
Flavia Chiuppesi, John A. Zaia, Paul Frankel, et al.
The Lancet Microbe (2022) Vol. 3, Iss. 4, pp. e252-e264
Open Access | Times Cited: 43
Nucleic acid degradation as barrier to gene delivery: a guide to understand and overcome nuclease activity
Heyang Zhang, Jo Vandesompele, Kevin Braeckmans, et al.
Chemical Society Reviews (2023) Vol. 53, Iss. 1, pp. 317-360
Closed Access | Times Cited: 30
Vaccine development: Current trends and technologies
Renu Poria, Deepak Kala, Rupak Nagraik, et al.
Life Sciences (2023) Vol. 336, pp. 122331-122331
Closed Access | Times Cited: 26
Broad-spectrum pan-genus and pan-family virus vaccines
Chee Wah Tan, Sophie Valkenburg, Leo L. M. Poon, et al.
Cell Host & Microbe (2023) Vol. 31, Iss. 6, pp. 902-916
Open Access | Times Cited: 22
COVID-19 Vaccines: Where Did We Stand at the End of 2023?
Kenneth Lundström
Viruses (2024) Vol. 16, Iss. 2, pp. 203-203
Open Access | Times Cited: 9
Plasmid DNA for Therapeutic Applications in Cancer
David Hernán Martínez-Puente, José J. Pérez‐Trujillo, Laura Mireya Zavala-Flores, et al.
Pharmaceutics (2022) Vol. 14, Iss. 9, pp. 1861-1861
Open Access | Times Cited: 33
Nucleocapsid as a next-generation COVID-19 vaccine candidate
Bryan Oronsky, Christopher Larson, Scott Caroen, et al.
International Journal of Infectious Diseases (2022) Vol. 122, pp. 529-530
Open Access | Times Cited: 30
The role of SARS-CoV-2 nucleocapsid protein in antiviral immunity and vaccine development
Haiyun Yu, Fei Guan, Heather Miller, et al.
Emerging Microbes & Infections (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 29
Nucleic acid-based vaccine platforms against the coronavirus disease 19 (COVID-19)
Roghayyeh Baghban, Abdolmajid Ghasemian, Shirin Mahmoodi
Archives of Microbiology (2023) Vol. 205, Iss. 4
Open Access | Times Cited: 19
The development of DNA vaccines against SARS-CoV-2
Kanwal Khalid, Chit Laa Poh
Advances in Medical Sciences (2023) Vol. 68, Iss. 2, pp. 213-226
Open Access | Times Cited: 17
Molecular characterization of SARS-CoV-2 nucleocapsid protein
Yanping Huang, Junkai Chen, Siwei Chen, et al.
Frontiers in Cellular and Infection Microbiology (2024) Vol. 14
Open Access | Times Cited: 6
The Key to Increase Immunogenicity of Next-Generation COVID-19 Vaccines Lies in the Inclusion of the SARS-CoV-2 Nucleocapsid Protein
Noe Juvenal Mendoza-Ramírez, Julio García‐Cordero, Gaurav Shrivastava, et al.
Journal of Immunology Research (2024) Vol. 2024, pp. 1-18
Open Access | Times Cited: 5
COVID-19 vaccines: A comprehensive review of safety and efficacy
Zhipeng Yan, Ming Yang, Ching‐Lung Lai
Elsevier eBooks (2025), pp. 685-777
Closed Access
Transformative Approaches in SARS-CoV-2 Management: Vaccines, Therapeutics and Future Direction
Ankita Saha, Shweta Choudhary, Priyanshu Walia, et al.
Virology (2025) Vol. 604, pp. 110394-110394
Closed Access
Immunobiology and immunotherapy of COVID-19
Kenneth Lundström
Progress in molecular biology and translational science (2025)
Closed Access
Viral vector and nucleic acid vaccines against COVID-19: A narrative review
Saeed Khoshnood, Roya Ghanavati, Maryam Shirani, et al.
Frontiers in Microbiology (2022) Vol. 13
Open Access | Times Cited: 25
Interim analysis from a phase 2 randomized trial of EuCorVac-19: a recombinant protein SARS-CoV-2 RBD nanoliposome vaccine
Jonathan F. Lovell, Yeong Ok Baik, Seuk Keun Choi, et al.
BMC Medicine (2022) Vol. 20, Iss. 1
Open Access | Times Cited: 25
Differential requirement of neutralizing antibodies and T cells on protective immunity to SARS-CoV-2 variants of concern
Patrick O. Azevedo, Natália Satchiko Hojo-Souza, Lídia Faustino, et al.
npj Vaccines (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 12
The use of electroporation to deliver DNA-based vaccines
D. N. Kisakov, Igor M. Belyakov, L.A. Kisakova, et al.
Expert Review of Vaccines (2023) Vol. 23, Iss. 1, pp. 102-123
Open Access | Times Cited: 12
DNA Vaccines for Epidemic Preparedness: SARS-CoV-2 and Beyond
Joel N. Maslow, Ijoo Kwon, Sagar B. Kudchodkar, et al.
Vaccines (2023) Vol. 11, Iss. 6, pp. 1016-1016
Open Access | Times Cited: 10
Harnessing T-Cells for Enhanced Vaccine Development against Viral Infections
Zhen Zhuang, Jianfen Zhuo, Yaochang Yuan, et al.
Vaccines (2024) Vol. 12, Iss. 5, pp. 478-478
Open Access | Times Cited: 3
Next-Generation Vaccines against COVID-19 Variants: Beyond the Spike Protein
Srinivasa Reddy Bonam, Haitao Hu
Zoonoses (2023) Vol. 3, Iss. 1
Open Access | Times Cited: 8
Page 1 - Next Page

Scroll to top